GlassScriptPhysician profile
Khurram Nazeer
NPI 1043291081
$3,261.25
in general payments reported to CMS, 2019-2025
21 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $87.91 · 2021: $296 · 2022: $302 · 2023: $849 · 2024: $491 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154 · Education: $33.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,154.34 |
| Education | $33.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $695.46 | 2021-2025 | Ultomiris |
| Travere Therapeutics, INC. | $368.74 | 2024-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $311.54 | 2020-2024 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $281.73 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $258.67 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Baxter Healthcare | $231.03 | 2019-2023 | Renal - Pd |
| Amgen INC. | $206.55 | 2019-2025 | Tavneos |
| Genzyme Corporation | $161.63 | 2023-2024 | |
| Abbott Laboratories | $149.89 | 2019 | |
| Nxstage Medical, INC. | $129.16 | 2019-2021 | |
| Vifor Pharma, INC. | $94.02 | 2019-2023 | Korsuva, Veltassa |
| Aurinia Pharma U.S., INC. | $70.48 | 2024-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $66.55 | 2023 | Tarpeyo |
| Glaxosmithkline, LLC. | $53.94 | 2023-2025 | Benlysta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $49.46 | 2022-2023 | Jynarque |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $30.82 | 2020 | |
| Mallinckrodt Hospital Products INC. | $21.69 | 2020 | |
| Kyowa Kirin, INC. | $21.10 | 2023 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $21.01 | 2024 | Eohilia |
| Ardelyx, INC. | $19.36 | 2025 | Ibsrela |
| Radiometer America, INC | $18.42 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khurram Nazeer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.